|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3(17009)2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F,
Hora M, Kuczyk MA, et al: European association of urology
guidelines on renal cell carcinoma: The 2019 update. Eur Urol.
75:799–810. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Saliby RM, Saad E, Labaki C, Xu W, Braun
DA, Viswanathan SR and Bakouny Z: Novel targeted therapies for
renal cell carcinoma: Building on the successes of vascular
endothelial growth factor and mTOR inhibition. Hematol Oncol Clin
North Am. 37:1015–1026. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Escudier B and Gore M: Axitinib for the
management of metastatic renal cell carcinoma. Drugs RD.
11:113–126. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bellesoeur A, Carton E, Alexandre J,
Goldwasser F and Huillard O: Axitinib in the treatment of renal
cell carcinoma: Design, development, and place in therapy. Drug Des
Devel Ther. 11:2801–2811. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tiako Meyo M, Chen J, Goldwasser F, Hirsch
L and Huillard O: A profile of avelumab plus axitinib in the
treatment of renal cell carcinoma. Ther Clin Risk Manag.
18:683–698. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hoshi S, Numahata K, Kanno H, Sato M,
Kuromoto A, Nezu K, Sakai T, Konno C, Ishizuka Y, Izumi H, et al:
Updated recommendation on molecular-targeted therapy for metastatic
renal cell cancer. Mol Clin Oncol. 7:591–594. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jakobsson M, Strambi A, Nilsson F,
Arpegård J and Dalén J: Real-world experience of second-line
axitinib in metastatic renal cell carcinoma: Analysis of the
Swedish population. Future Oncol. 20:1385–1392. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Powles T, Albiges L, Bex A, Comperat E,
Grünwald V, Kanesvaran R, Kitamura H, McKay R, Porta C, Procopio G,
et al: Renal cell carcinoma: ESMO Clinical Practice Guideline for
diagnosis, treatment and follow-up. Ann Oncol. 35:692–706.
2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Figlin RA, Kaufmann I and Brechbiel J:
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New
strategies for overcoming resistance to VEGFR and mTORC1
inhibitors. Int J Cancer. 133:788–796. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sweeney PL, Suri Y, Basu A, Koshkin VS and
Desai A: Mechanisms of tyrosine kinase inhibitor resistance in
renal cell carcinoma. Cancer Drug Resist. 6:858–873.
2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ou X, Gao G, Habaz IA and Wang Y:
Mechanisms of resistance to tyrosine kinase inhibitor-targeted
therapy and overcoming strategies. MedComm (2020).
5(e694)2024.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Nakayama Y, Enomoto D, Yamamoto K and
Takara K: Molecular characteristics of everolimus-resistant renal
cell carcinoma cells generated by continuous exposure to
everolimus. Anticancer Res. 43:4349–4357. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nakayama Y, Ino A, Yamamoto K and Takara
K: Down-regulation of ABCB1 in everolimus-resistant renal cell
carcinoma cells. Anticancer Res. 44:2871–2876. 2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fujita M, Tohji C, Honda Y, Yamamoto Y,
Nakamura T, Yagami T, Yamamori M and Okamura N: Cytotoxicity of
15-deoxy-Δ(12,14)-prostaglandin J(2) through PPARγ-independent
pathway and the involvement of the JNK and Akt pathway in renal
cell carcinoma. Int J Med Sci. 9:555–566. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen Y, Tortorici MA, Garrett M, Hee B,
Klamerus KJ and Pithavala YK: Clinical pharmacology of axitinib.
Clin Pharmacokinet. 52:713–725. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rini BI, Garrett M, Poland B, Dutcher JP,
Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J and
Motzer RJ: Axitinib in metastatic renal cell carcinoma: Results of
a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol.
53:491–504. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Fukudo M, Tamaki G, Azumi M, Kakizaki H,
Matsumoto S and Tasaki Y: Absorption of the orally active
multikinase inhibitor axitinib as a therapeutic index to guide dose
titration in metastatic renal cell carcinoma. Invest New Drugs.
39:595–604. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Takara K, Sakaeda T, Yagami T, Kobayashi
H, Ohmoto N, Horinouchi M, Nishiguchi K and Okumura K: Cytotoxic
effects of 27 anticancer drugs in HeLa and MDR1-overexpressing
derivative cell lines. Biol Pharm Bull. 25:771–778. 2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nakayama Y, Ino A, Yamamoto K and Takara
K: Involvement of everolimus-induced ABCB1 downregulation in
drug-drug interactions. Biomed Rep. 21(184)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Takara K, Obata Y, Yoshikawa E, Kitada N,
Sakaeda T, Ohnishi N and Yokoyama T: Molecular changes to HeLa
cells on continuous exposure to cisplatin or paclitaxel. Cancer
Chemother Pharmacol. 58:785–793. 2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Takara K, Kitada N, Yoshikawa E, Yamamoto
K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N and Yokoyama T:
Molecular changes to HeLa cells on continuous exposure to SN-38, an
active metabolite of irinotecan hydrochloride. Cancer Lett.
278:88–96. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kitada N, Takara K, Minegaki T, Itoh C,
Tsujimoto M, Sakaeda T and Yokoyama T: Factors affecting
sensitivity to antitumor platinum derivatives of human colorectal
tumor cell lines. Cancer Chemother Pharmacol. 62:577–584.
2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Minegaki T, Takara K, Hamaguchi R,
Tsujimoto M and Nishiguchi K: Factors affecting the sensitivity of
human-derived esophageal carcinoma cell lines to 5-fluorouracil and
cisplatin. Oncol Lett. 5:427–434. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Poller B, Iusuf D, Sparidans RW, Wagenaar
E, Beijnen JH and Schinkel AH: Differential impact of
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)
on axitinib brain accumulation and oral plasma pharmacokinetics.
Drug Metab Dispos. 39:729–735. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Thomas-Schoemann A, Blanchet B, Bardin C,
Noé G, Boudou-Rouquette P, Vidal M and Goldwasser F: Drug
interactions with solid tumour-targeted therapies. Crit Rev Oncol
Hematol. 89:179–196. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sato H, Siddig S, Uzu M, Suzuki S, Nomura
Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, et al:
Elacridar enhances the cytotoxic effects of sunitinib and prevents
multidrug resistance in renal carcinoma cells. Eur J Pharmacol.
746:258–266. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Beretta GL, Cassinelli G, Pennati M, Zuco
V and Gatti L: Overcoming ABC transporter-mediated multidrug
resistance: The dual role of tyrosine kinase inhibitors as
multitargeting agents. Eur J Med Chem. 142:271–289. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lieu CH, Tran H, Jiang ZQ, Mao M, Overman
MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, et al: The
association of alternate VEGF ligands with resistance to anti-VEGF
therapy in metastatic colorectal cancer. PLoS One.
8(e77117)2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Alkafaas SS, Elsalahaty MI, Ismail DF,
Radwan MA, Elkafas SS, Loutfy SA, Elshazli RM, Baazaoui N, Ahmed
AE, Hafez W, et al: The emerging roles of sphingosine 1-phosphate
and SphK1 in cancer resistance: A promising therapeutic target.
Cancer Cell Int. 24(89)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bao JM, Zhi X, Yuan HY, Chen TY, Chen MK,
Zhou JH, Xue KY, Yang JK and Liu CD: Overexpression of SPHK1
associated with targeted therapy resistance in predicting poor
prognosis in renal cell carcinoma. Transl Cancer Res. 12:572–584.
2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Walliser C, Hermkes E, Schade A, Wiese S,
Deinzer J, Zapatka M, Désiré L, Mertens D, Stilgenbauer S and
Gierschik P: The phospholipase Cγ2 mutants R665W and L845F
identified in ibrutinib-resistant chronic lymphocytic leukemia
patients are hypersensitive to the Rho GTPase Rac2 protein. J Biol
Chem. 291:22136–22148. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pasqualucci L: Epigenetic rewiring of BCR
signaling as a novel mechanism of ibrutinib resistance in
ABC-DLBCL. Blood Cancer Discov. 2:555–558. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shaffer AL III, Phelan JD, Wang JQ, Huang
D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, et
al: Overcoming acquired epigenetic resistance to BTK inhibitors.
Blood Cancer Discov. 2:630–647. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wu W, Wang W, Franzen CA, Guo H, Lee J, Li
Y, Sukhanova M, Sheng D, Venkataraman G, Ming M, et al: Inhibition
of B-cell receptor signaling disrupts cell adhesion in mantle cell
lymphoma via RAC2. Blood Adv. 5:185–197. 2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lin WH, Cooper LM and Anastasiadis PZ:
Cadherins and catenins in cancer: Connecting cancer pathways and
tumor microenvironment. Front Cell Dev Biol.
11(1137013)2023.PubMed/NCBI View Article : Google Scholar
|
